Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mavacamten. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | PDE9A | O76083 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.36 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.36 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.36 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.36 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.36 |
| ▸ | ATP1B3 | P54709 | 3/20 | 0.36 |
| ▸ | FXYD2 | P54710 | 3/20 | 0.36 |
| ▸ | ATP1A4 | Q13733 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mavacamten SCHEMBL16320785 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2B6SMN1; SMN2HTTMEN1 | |
| Mavacamten SCHEMBL16356131 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2B6SMN1; SMN2HTTMEN1 | |
| Mavacamten SCHEMBL29478185 | 0.92 | CYP3A4 (0.85) | CYP3A4CYP2B6SMN1; SMN2HTTMEN1 | |
| SCHEMBL16356141 | 0.87 | CYP3A4 (0.78) | CYP3A4CYP2B6SMN1; SMN2HTTMEN1 | |
| SCHEMBL16320868 | 0.87 | CYP3A4 (0.76) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB | |
| SCHEMBL16324428 | 0.87 | CYP3A4 (0.76) | CYP3A4CYP2B6SMN1; SMN2HTTMEN1 | |
| SCHEMBL16320866 | 0.87 | CYP3A4 (0.76) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB | |
| SCHEMBL16356126 | 0.87 | CYP3A4 (0.76) | CYP3A4CYP2B6SMN1; SMN2HTTMEN1 | |
| SCHEMBL16324429 | 0.87 | CYP3A4 (0.76) | CYP3A4CYP2B6SMN1; SMN2HTTMEN1 | |
| SCHEMBL16324389 | 0.87 | CYP3A4 (0.76) | CYP3A4CYP2B6SMN1; SMN2HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744664-A2 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MyoKardia, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12616697-B2 | Methods of treatment with myosin modulator | MyoKardia, Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250360132-A1 | METHODS OF ADMINISTERING MYOSIN INHIBITORS | MYOKARDIA INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250288586-A1 | Methods of Administering Myosin Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2025-09-18 | — | — | US | disclosed |
| US-20240382486-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2024-11-21 | — | — | US | disclosed |
| US-20240299390-A1 | Methods of Treatment with Myosin Modulator | MyoKardia, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-RE50050-E1 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240180887-A1 | USE OF PPAR(gamma) AGONISTS OR MPC INHIBITORS FOR TREATING PRIMARY, INNATE DISEASES OF THE CARDIAC MUSCLE (CARDIOMYOPATHIES) | PREVENTAGE THERAPEUTICS GMBH (DE) | 2024-06-06 | — | — | US | disclosed |
| US-20240115568-A1 | Methods of Administering Myosin Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2024-04-11 | — | — | US | disclosed |
| WO-2023211872-A1 | METHODS OF ADMINISTERING MYOSIN INHIBITORS | MyoKardia, Inc. (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-3010910-B1 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MYOKARDIA INC (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2019028360-A1 | MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY | MyoKardia, Inc. (US) | 2019-02-07 | — | — | WO | disclosed |
| US-20180311242-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2018-11-01 | — | — | US | disclosed |
| US-20170281626-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-9585883-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-3010910-A1 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | Myokardia, Inc. (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20160030428-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2016-02-04 | — | — | US | disclosed |
| US-9181200-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2014-12-25 | — | — | US | disclosed |
| WO-2014205223-A1 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MyoKardia, Inc. (US) | 2014-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885SMN1; SMN2 1177/4885 |
| US-20240299390-A1 | Methods of Treatment with Myosin Modulator | MYH10, MYH2, MYO3A | CYP3A4 4745/4885CYP2B6 4760/4885SMN1; SMN2 1033/4885 |
| US-20240382486-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885SMN1; SMN2 1177/4885 |
| US-20160030428-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885SMN1; SMN2 1177/4885 |
| US-12616697-B2 | Methods of treatment with myosin modulator | MYH2, MYH14, MYH10 | CYP3A4 3296/4885CYP2B6 4375/4885SMN1; SMN2 969/4885 |
| US-20170281626-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885SMN1; SMN2 1177/4885 |
| US-20250360132-A1 | METHODS OF ADMINISTERING MYOSIN INHIBITORS | MYH2, MYLK2, MYH10 | CYP3A4 3078/4885CYP2B6 3439/4885SMN1; SMN2 283/4885 |
| US-20180311242-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885SMN1; SMN2 1177/4885 |
| US-20250288586-A1 | Methods of Administering Myosin Inhibitors | MYH2, MYLK2, MYH10 | CYP3A4 3078/4885CYP2B6 3439/4885SMN1; SMN2 283/4885 |
| US-20240115568-A1 | Methods of Administering Myosin Inhibitors | MYH2, MYLK2, MYH10 | CYP3A4 3078/4885CYP2B6 3439/4885SMN1; SMN2 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.